Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
Open accessThe DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index.
Abstract
Introduction: Current treatment options for major depressive disorder (MDD) have limited efficacy and are associated with adverse effects. Recent studies investigating the antidepressant effect of serotonergic psychedelics—also known as classic psychedelics—have promising preliminary results with large effect sizes. In this context, we conducted a review of the putative neurobiological underpinnings of the mechanism of antidepressant action of these drugs. Methods: A narrative review was conducted using PubMed to identify published articles evaluating the antidepressant mechanism of action of serotonergic psychedelics. Results: Serotonergic psychedelics have serotonin (5HT)2A agonist or partial agonist effects. Their rapid antidepressant effects may be mediated—in part—by their potent 5HT2A agonism, leading to rapid receptor downregulation. In addition, these psychedelics impact brain derived neurotrophic factor and immunomodulatory responses, both of which may play a role in their antidepressant effect. Several neuroimaging and neurophysiology studies evaluating mechanistic change from a network perspective can help us to further understand their mechanism of action. Some, but not all, data suggest that psychedelics may exert their effects, in part, by disrupting the activity of the default mode network, which is involved in both introspection and self-referential thinking and is over-active in MDD. Conclusion: The mechanisms of action underlying the antidepressant effect of serotonergic psychedelics remains an active area of research. Several competing theories are being evaluated and more research is needed to determine which ones are supported by the most robust evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with SSRIs, their enhancement of serotonergic transmission is likely relevant to their antidepressant effects through downstream changes in gene expression, indirect effects on glutamatergic and dopaminergic systems, and changes in emotional and cognitive brain networks, summarized in recent reviews [128, 129].”
From Beyond the serotonin deficit hypothesis: Communicating a neuroplasticity framework of major depressive disorder (2024) · cites this paper as [128]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729 · cited 2×
“Similar findings are reported for other inflammatory markers such as IL-1β, CRP, and TNF-α (50, 53).”
BackgroundRequirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“SSRIs increase neurogenesis (40) and their behavioral effects can be blocked by its disruption (41).”
BackgroundThe molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889 · cited 1×
“Depressive symptoms have been linked to insufficient neurogenesis and neurotrophic activity (39).”
BackgroundGriffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
A functional anatomical study of unipolar depression
Drevets, W., Videen, T., Price, J., Preskorn, S., Carmichael, S., & Raichle, M. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-09-03628.1992 · Cited by 1,266
Cited by
Page, C. E., Epperson, C. N., Novick, A. M., Duffy, K. A., & Thompson, S. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02625-2 · Cited by 80
“…enhancement of serotonergic transmission is likely relevant to their antidepressant effects through downstream changes in gene expression, indirect effects on glutamatergic and dopaminergic systems, and changes in emotional and cognitive brain networks, summarized in recent reviews [128, 129].”
Husain, M. I., Blumberger, D. M., Castle, D. J., Ledwos, N., Fellows, E., Jones, B. D. M., Ortiz, A., Kloiber, S. M., Wang, W., Rosenblat, J. D., et al. (2023) · BJPsych Open · doi:10.1192/bjo.2023.535 · Cited by 57
Self-citationPsychedelic therapy in depression and substance use disorders
Korkmaz, N. D., Çıkrıkçılı, U., Akan, M., & Yücesan, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16421 · Cited by 32
Serotonergic neuromodulation of synaptic plasticity
Higa, G. S. V., Viana, F. J. C., Francis-Oliveira, J., Cruvinel, E., Franchin, T. S., Marcourakis, T., Ulrich, H., & De Pasquale, R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110036 · Cited by 29
Psychedelics as Therapeutics—Potential and Challenges
Volkow, N. D., Gordon, J. A., & Wargo, E. M. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.1968 · Cited by 29
Williams, Z. J., Barnett, H., & Szigeti, B. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.4809 · Cited by 29
Werle, I., & Bertoglio, L. J. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105899 · Cited by 26
Spirituality as a Therapeutic Approach for Severe Mental Illness: Insights from Neural Networks
Knegtering, H., Bruggeman, R., & Spoelstra, S. K. (2024) · Religions · doi:10.3390/rel15040489 · Cited by 25
Novel rapid treatment options for adolescent depression
Ledesma‐Corvi, S., Jornet-Plaza, J., Gálvez‐Melero, L., & García-Fuster, M. J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107085 · Cited by 25
Ruffini, G., Castaldo, F., Lopez-Sola, E., Sanchez-Todo, R., & Vohryzek, J. (2024) · Entropy · doi:10.3390/e26110953 · Cited by 27
Solaja, I., Haldane, K., Mason, N. L., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105570 · Cited by 23
Silverstein, B. H., Kolbman, N., Nelson, A., Liu, T., Guzzo, P. R., Gilligan, J., Lee, U., Mashour, G. A., Vanini, G., & Pal, D. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03308-4 · Cited by 20
Downey, A. E., Chaphekar, A. V., Woolley, J. D., & Raymond‐Flesch, M. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01005-z · Cited by 17
Psychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats
Ferri, B. G., Novais, C. O., Bonani, R. S., de Barros, W. A., de Fátima, Â., Vilela, F. C., & Giusti‐Paiva, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175926 · Cited by 13
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 12
Amaev, A., Song, J., Kambari, Y., Carmona-Torres, E., Abdolizadeh, A., Ueno, F., Koizumi, T., Strafella, A. P., Husain, M. I., Graff‐Guerrero, A., et al. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.03.022 · Cited by 11
Self-citationLashgari, N., Khalaji, M., Rana, P., Badrabadi, F., Rahnama, M., Nasoori, H., Roudsari, N. M., Nia, M. M. K., & Shafaroodi, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05097-9 · Cited by 10
Wong, S., Meckling, G., Fabiano, N., Lee, S., Jones, B. D. M., Shorr, R., Dargél, A., Davis, A. K., Fiedorowicz, J. G., Solmi, M., et al. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251372449 · Cited by 10
Self-citationMaldegem, M. V., Vohryzek, J., Atasoy, S., Alnagger, N., Cardone, P., Bonhomme, V. L., Vanhaudenhuyse, A., Demertzi, A., Jaquet, O., Bahri, M. A., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.12.036 · Cited by 10
Gendra, J. C., Lopez-Sola, E., Castaldo, F., Lleal-Custey, È., Sanchez-Todo, R., Vohryzek, J., Salvador, R., Andrzejak, R. G., Ruffini, G., & Initiative, T. A. D. N. (2026) · Network Neuroscience · doi:10.1162/netn.a.540 · Cited by 8
Zhu, H., Liu, X., Wang, X., Li, Y., Ma, F., Tan, B., Zhou, P., Fu, F., & Su, R. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176038 · Cited by 8
Kupferberg, A., & Hasler, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1372650 · Cited by 7
Biomarkers of Affective Dysregulation Associated with In Utero Exposure to EtOH
Darbinian, N., Merabova, N., Tatevosian, G., Morrison, M. F., Darbinyan, A., Zhao, H., Goetzl, L. M., & Selzer, M. E. (2023) · Cells · doi:10.3390/cells13010002 · Cited by 7
de Araújo, J. I. F., do Nascimento, G. A., Vieira‐Neto, A. E., Magalhães, F. E. A., & Campos, A. R. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115415 · Cited by 7
Barber, M., Gardner, J., Liknaitzky, P., & Carter, A. (2024) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/papt.12545 · Cited by 6
Arinaga, M., Yamada, J., Maeda, S., Okamura, A., Oshima, Y., Zhang, L., Han, Y., Iinuma, K., & Jinno, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157519 · Cited by 6
Ludbrook, G., Bryson, N., Taylor, B., Hocevar‐Trnka, J., Johnson, M. W., Hirman, J., Morrish, G. A., Alexander, R., & Pollack, M. H. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002047 · Cited by 5
Is Use of Psychedelic Drugs a Risk or Protective Factor for Late-Life Cognitive Decline?
Fearn, K., & Bhattacharyya, K. K. (2024) · Gerontology and Geriatric Medicine · doi:10.1177/23337214241250108 · Cited by 5
Sabbah, S. G., Li, S., Wong, S., Le, G. H., Badulescu, S., Hawco, C. S., Rosenblat, J. D., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120335 · Cited by 5
Self-citationA unified pathogenic hypothesis for mental disorders based on schismogenesis
García-Toro, M., & Gómez-Juanes, R. (2025) · Biosystems · doi:10.1016/j.biosystems.2025.105431 · Cited by 4
Tudorancea, I.-M., Stanciu, G. D., Torrent, C., Madero, S., Hriţcu, L., & Tamba, B.-I. (2025) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2025.2499458 · Cited by 4
The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry
Soylemez, K. K., de Boo, E. M., Susuzlu, A., & Lusher, J. M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15100450 · Cited by 4
Moshfeghinia, R., Mostafavi, S., Jazi, K., Ghasemi, A. R., Khosravani-Nezhad, Y., Narayanan, S., Ahmadi, J., & Pasalar, M. (2026) · BMC Psychology · doi:10.1186/s40359-025-03935-y · Cited by 4
Anchesi, I., Astorino, M. F., Raffaele, I., Donato, D. S., Silvestro, S., Minuti, A., Calabrò, M., Scuruchi, M., & Cipriano, G. L. (2025) · Cells · doi:10.3390/cells14231872 · Cited by 3
Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need
de Jonge, D., van der Meer, P. B., Kramers, C., & Schellekens, A. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01567-4 · Cited by 3
The Therapeutic Potential of Psychedelics on Reducing Rumination: A Mini-Review
Ramarushton, B., Blumenthal, H., Ryals, A. J., Boals, A., & Thompson, L. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0009 · Cited by 3
Dost, D., Benyamina, A., & Karila, L. (2024) · L Encéphale · doi:10.1016/j.encep.2024.02.007 · Cited by 2
Chisamore, N., Kaczmarek, E. S., Doyle, Z., Johnson, D. E., Weiglein, G., Meshkat, S., Brudner, R. M., Blainey, M. G., Riva-Cambrin, J., McIntyre, R. S., et al. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251328316 · Cited by 2
Self-citationExperience, plasticity, and context: Beyond single-level models of antidepressant action
Eckert, D. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261473402 · Cited by 1
Vázquez, G. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33580-8.00022-2
Wittenkeller, L. M., Gudelsky, G. G., Winhusen, T. M., & Amato, D. (2026) · Research Square · doi:10.21203/rs.3.rs-8544354/v1
Estela-Fernandez, C. A., Elsheikh, R. M. Y., Beatrice, D. F., Alhendal, A. A., Ewe, C. I., Montesinos, S. Y., Wensel, J., Mishra, A. P., Yousif, A. A., & Ali, H. T. (2026) · Neuropsychiatrie · doi:10.1007/s40211-026-00584-4
Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review
van der Meer, P. B., Schukking, N., Dik, M., van Reemst, A., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., Verboeket, S. O., de Waal, M. M., Goudriaan, A. E., et al. (2025) · Psychedelic Medicine · doi:10.1177/28314425251364182
Ritual to Relief: Ethical Frontiers in Repurposing Psychoactive Substances
O’Leary, E., Dodd, S., & Stahl, S. M. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.003
Jankowska, E., & Świeczkowski, D. (2026) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2026.2729740
Moving beyond 5-HT2A: language models map neurotransmitter receptors to experiential semantics
Suresh, P., Kins, J., Levkovskyy, L., Thieme, A., Wren, P. B., Ray, T., Barrett, F. S., Carhart-Harris, R. L., & Bzdok, D. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07170-0
Canale, L., Raval, D., Chatha, P., Penn, K., Weber, C. G., Stout, C., & Weleff, J. (2023) · American Journal of Psychiatry Residents Journal · doi:10.1176/appi.ajp-rj.2023.190103
Meshkat, S., Leung, M., Meshkat, S., Lin, Q., Wijendran, D., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A. J., et al. (2026) · CNS Drugs · doi:10.1007/s40263-026-01325-5
Johnston, J. N., Jones, G. H., Peng, S., Yuan, P., Yavi, M., Kadriu, B., Henter, I. D., Quintanilla, B., Elkahloun, A. G., Moaddel, R., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03768-0
Feitosa, N. D. A., Sousa, A. J. O., de Araújo, M. C. F., Lima, J. F., do Nascimento, J. E. T., Sobreira, F. R. S., Assis, C. E. B. S. D., Silva, H. A. M. D., Lima, G. F., & de Araújo, J. I. F. (2026) · Disciplinarum Scientia | Naturais e Tecnológicas · doi:10.37779/nt.v27i1.5714
Guanoluisa, M. J. C., & Cedeño, A. V. T. (2026) · Universidad Politécnica Salesiana Repositorio Digital (Universidad Politécnica Salesiana)
The Effects of Psychedelic-Assisted Therapy on Illness and Death Anxiety
Amaev, A. (2024) · TSpace (University of Toronto)
Associations between individual symptoms of Major Depressive Disorder and peripheral inflammation
Fellows, E. (2024) · TSpace (University of Toronto)
Self-citationRocha, R. G. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Farmácia da Boa Hora, Porto e nos Serviços Farmacêuticos do Hospital Lusíadas, Porto
Leite, A. S. M. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/nvv1-9m13
Personalized Medicine in Psychiatry
(2026) · MDPI eBooks · doi:10.3390/books978-3-7258-7375-3
Cunha, C. D. S. (2025) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Metadata
- Authors
- Husain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- University Health Network (CA)
- Corresponding author
- Husain, Muhammad Ishrat
- ORCID
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-02-10
- Volume
- 13
- Pages
- 1076459-1076459
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC9950579
- OpenAlex
- W4319984222
- Cited by
- 50
- References
- 96
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 17 · 2023: 6
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- Funders
- Patient-Centered Outcomes Research Institute
- Fondation Brain Canada
- Sunovion
- Indivior
- Centre for Addiction and Mental Health Foundation
- BrainsWay
- Physicians' Services Incorporated Foundation
- University of Toronto
- Grand Challenges Canada
- Servier
- H. Lundbeck A/S
- Seqirus
- National Institutes of Health
- Allergan
- Canadian Institutes of Health Research
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- serotonergic psychedelics, classic psychedelics, major depressive disorder, antidepressant mechanism, 5-HT2A receptor agonism, receptor down-regulation, brain-derived neurotrophic factor, immunomodulation, default mode network, neuroimaging, neurophysiology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.